Ondine Biomedical Inc (LON: OBI), a provider of photodisinfection-based therapies, announced on Wednesday that it has secured acceptance of two abstracts for poster presentation at the World Congress on Infectious Diseases, taking place from 25 June 2026 to 27 June 2026 in Barcelona, Spain.

These abstracts present long-term clinical and economic data on the company's light-activated antimicrobial technology in surgical settings, including eight-year longitudinal results demonstrating improved outcomes compared with traditional antibiotic treatments.

One study reports a 66% reduction in surgical site infections in spine surgery using nasal photodisinfection, alongside sustained cost savings and no evidence of antimicrobial resistance. The second highlights under-reporting of cardiac surgical site infections, identifying shortcomings in cost and incidence methodologies that may limit improvements in infection control.

The presentations will be delivered in the virtual poster category, providing international visibility for Ondine Biomedical's research targeting antimicrobial resistance and infection prevention.